European urology最新文献_第3页

Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer 关于Enfortumab Vedotin 和 Pembrolizumab 用于未经治疗的晚期尿路上皮癌。

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.03.029

引用次数: 0

Reply to Hein V. Stroomberg, Klaus Brasso, and Andreas Røder’s Letter to the Editor re: Michael Baboudjian, Romain Diamand, Alessandro Uleri, et al. Does Overgrading on Targeted Biopsy of Magnetic Resonance Imaging–visible Lesions in Prostate Cancer Lead to Overtreatment? Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.003 回复 Hein V. Stroomberg、Klaus Brasso 和 Andreas Røder 致编辑的信，内容涉及：Michael Baboudjian、Romain Diamand、Alessandro Uleri 等：《前列腺癌磁共振成像可见病灶的靶向活检过度评级是否会导致过度治疗？欧洲泌尿外科杂志》。https://doi.org/10.1016/j.eururo.2024.02.003.

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.05.017

引用次数: 0

High-performing, Accessible, and Affordable Imaging in Metastatic Prostate Cancer: Is Whole-body Magnetic Resonance Imaging the Answer? 转移性前列腺癌的高性能、可及性和可负担性成像：全身磁共振成像是答案吗？

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.05.028

引用次数: 0

EVEREST: Attempting the Summit with Adjuvant Everolimus To Treat High-risk Renal Cell Carcinoma After Surgery EVEREST：用依维莫司辅助治疗手术后高风险肾细胞癌的 "巅峰尝试"。

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.05.024

引用次数: 0

Reply to Anwar R. Padhani, Frederic LeCouvet, Giuseppe Petralia, and Dow-Mu Koh’s Letter to the Editor re: Alonso Garcia-Ruiz, Carlos Macarro, Francesca Zacchi, et al. Whole-body Magnetic Resonance Imaging as a Treatment Response Biomarker in Castration resistant Prostate Cancer with Bone Metastases: The iPROMET Clinical Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.02.016 回复 Anwar R. Padhani、Frederic LeCouvet、Giuseppe Petralia 和 Dow-Mu Koh 致编辑的信：Alonso Garcia-Ruiz、Carlos Macarro、Francesca Zacchi 等：《全身磁共振成像作为骨转移钙化抵抗性前列腺癌的治疗反应生物标志物》：iPROMET临床试验》。Eur Urol.https://doi.org/10.1016/j.eururo.2024.02.016.

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.05.011

引用次数: 0

PRECISE v2: An Enhanced Framework To Guide Future Research on the Use of Magnetic Resonance Imaging in Prostate Cancer Active Surveillance PRECISE v2：PRECISE v2：指导未来在前列腺癌主动监测中使用磁共振成像研究的增强框架。

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.05.019

引用次数: 0

All Biochemical Recurrences Are Equal, but Some Are More Equal than Others 所有生化复发都是相同的，但有些比其他更相同。

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.05.020

引用次数: 0

Underactive Bladder According to the European Association of Urology Guidelines 根据欧洲泌尿学协会指南，膀胱功能不全。

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.04.028

引用次数: 0

Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial 在 GÖTEBORG-2 前列腺癌筛查试验中，4Kscore 作为前列腺特异性抗原反射测试的性能。

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.04.037

{"title":"Performance of 4Kscore as a Reflex Test to Prostate-specific Antigen in the GÖTEBORG-2 Prostate Cancer Screening Trial","authors":"","doi":"10.1016/j.eururo.2024.04.037","DOIUrl":"10.1016/j.eururo.2024.04.037","url":null,"abstract":"<div><h3>Background and objective</h3><p>We investigated whether adding 4Kscore as a reflex test to prostate-specific antigen (PSA) could improve the screening algorithm for prostate cancer (PC).</p></div><div><h3>Methods</h3><p>In the GÖTEBORG-2 PC screening trial, 38 000men (50–60 yr) were invited to PSA testing and, if elevated, followed by magnetic resonance imaging (MRI). For 571 men with PSA ≥3.0 ng/ml and evaluable outcomes, 4Kscore was calculated. The performance using a prespecified 4Kscore cutoff of 7.5% was evaluated.</p></div><div><h3>Key findings and limitations</h3><p>The area under the curve for 4Kscore to identify intermediate- and high-risk PC was 0.84 (95% confidence interval 0.79–0.89), and the positive predictive value, and negative predictive value were 15% (0.12–0.20) and 99% (97–100%), respectively. Of the 54 men diagnosed with intermediate- or high-grade PC, two had a 4Kscore cutoff below 7.5%, both with organ-confined intermediate-risk PC. Per 1000 men with elevated PSA, adding 4Kscore would have resulted in avoidance of MRI for 408 (41%) men, biopsies for 95 (28% reduction) men, and diagnosis of 23 low-grade cancers (23% reduction) while delaying the diagnosis of four men with intermediate-grade cancers (4%).</p></div><div><h3>Conclusions and clinical implications</h3><p>Including 4Kscore as a reflex test for men with elevated PSA reduces the need for MRI and biopsy markedly, and results in less overdiagnosis of low-grade PC at the cost of delaying the diagnosis of intermediate-grade PC in a few men. These results add further evidence for including new blood-based biomarkers in addition to PSA to improve the harm and benefit ratio of PC screening and reduce the need for resource-demanding MRI and biopsies.</p></div>","PeriodicalId":12223,"journal":{"name":"European urology","volume":null,"pages":null},"PeriodicalIF":25.3,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0302283824023790/pdfft?md5=7d0e2d2d1eb971419908d4b78945e382&pid=1-s2.0-S0302283824023790-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141077404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Re: Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer 关于Enfortumab Vedotin 和 Pembrolizumab 用于未经治疗的晚期尿路上皮癌。

IF 25.3 1区医学

European urology Pub Date : 2024-09-01 DOI: 10.1016/j.eururo.2024.03.032

引用次数: 0